An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Veracyte (Nasdaq: VCYT) announced that seven abstracts showcasing findings from the Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting from April 28 to May 1, 2023, in Chicago. The abstracts emphasize the clinical utility of the Decipher Prostate Genomic Classifier, aiding treatment decisions for prostate cancer patients. Notable presentations include studies on Molecular Correlates with PSMA Expression and the Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome. Veracyte aims to utilize this research to enhance patient care and treatment outcomes, reinforcing its commitment to evidence-based cancer treatment.
Positive
Seven abstracts presented at AUA 2023 highlight the clinical utility of Decipher Prostate Genomic Classifier.
Studies reinforce the effectiveness of Decipher tests in informing treatment decisions for prostate cancer.
Commitment to evidence-based cancer care is showcased through real-world impact research.
Negative
None.
Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-scale studies that reinforce the real-world clinical utility of the company’s Decipher Prostate Genomic Classifier, which helps inform treatment decisions for men with prostate cancer.
“The volume and quality of Decipher data being presented at AUA 2023 reinforce Veracyte’s ongoing commitment to evidence-based care and to advancing our understanding of urologic cancers. We are particularly excited about new data demonstrating the real-world impact of our Decipher Prostate test on patient care and outcomes,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
Following are details of the Decipher abstracts accepted for presentation at the AUA 2023 meeting:
Andrea Necchi, M.D., Vita-Salute San Raffaele University
Location:
McCormick Place, S404A
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that the Decipher Prostate test may have a real-world impact on patient care and outcomes. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2022, and our Quarterly Report on Form 10-Q filed for the three months ended December 31, 2022. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com/. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte delivers the Decipher Prostate Genomic Classifier from its CLIA laboratories. Those tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation. This piece is distributed purely for educational purposes and is not intended to promote or encourage any off-label use of Veracyte products.
Media:
Tracy Morris Vice President of Global Corporate Communications tracy.morris@veracyte.com
650-380-4413
Source: Veracyte, Inc.
FAQ
What is the significance of the abstracts presented by Veracyte at AUA 2023?
The abstracts highlight the clinical utility of the Decipher Prostate Genomic Classifier, reinforcing its role in treatment decisions for prostate cancer.
When and where will the AUA Annual Meeting take place?
The AUA Annual Meeting will occur from April 28 to May 1, 2023, at McCormick Place in Chicago.
How does the Decipher Prostate Genomic Classifier impact patient care?
The Decipher Prostate Genomic Classifier aids healthcare providers in making informed treatment decisions, potentially improving patient outcomes.
What research findings were shared about Decipher tests at the meeting?
Findings include studies on molecular correlates with PSMA expression and the association of the Decipher Genomic Classifier with prostate cancer outcomes.
Who is presenting the Decipher abstract on April 28, 2023?
Dr. Adam Weiner from UCLA Health will present the abstract on Molecular Correlates with PSMA Expression in Prostate Cancer.
